251 related articles for article (PubMed ID: 32220892)
1. Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy.
Yang L; Shen C; Pettit CJ; Li T; Hu AJ; Miller ED; Zhang J; Lin SH; Williams TM
Clin Cancer Res; 2020 Jul; 26(14):3740-3750. PubMed ID: 32220892
[TBL] [Abstract][Full Text] [Related]
2. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress.
Cuneo KC; Morgan MA; Davis MA; Parcels LA; Parcels J; Karnak D; Ryan C; Liu N; Maybaum J; Lawrence TS
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):782-90. PubMed ID: 26975930
[TBL] [Abstract][Full Text] [Related]
3. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair.
Kausar T; Schreiber JS; Karnak D; Parsels LA; Parsels JD; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
Neoplasia; 2015 Oct; 17(10):757-66. PubMed ID: 26585231
[TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.
Karnak D; Engelke CG; Parsels LA; Kausar T; Wei D; Robertson JR; Marsh KB; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
Clin Cancer Res; 2014 Oct; 20(19):5085-96. PubMed ID: 25117293
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the
Iannuzzi CA; Indovina P; Forte IM; Di Somma S; Malfitano AM; Bruno M; Portella G; Pentimalli F; Giordano A
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33020398
[TBL] [Abstract][Full Text] [Related]
6. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
Parsels LA; Parsels JD; Tanska DM; Maybaum J; Lawrence TS; Morgan MA
Cell Cycle; 2018; 17(9):1076-1086. PubMed ID: 29895190
[TBL] [Abstract][Full Text] [Related]
7. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.
Bridges KA; Hirai H; Buser CA; Brooks C; Liu H; Buchholz TA; Molkentine JM; Mason KA; Meyn RE
Clin Cancer Res; 2011 Sep; 17(17):5638-48. PubMed ID: 21799033
[TBL] [Abstract][Full Text] [Related]
8. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
9. G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1.
Busch CJ; Kröger MS; Jensen J; Kriegs M; Gatzemeier F; Petersen C; Münscher A; Rothkamm K; Rieckmann T
Radiother Oncol; 2017 Feb; 122(2):260-266. PubMed ID: 27939202
[TBL] [Abstract][Full Text] [Related]
10. Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress.
Lindemann A; Patel AA; Tang L; Tanaka N; Gleber-Netto FO; Bartels MD; Wang L; McGrail DJ; Lin SY; Frank SJ; Frederick MJ; Myers JN; Osman AA
Mol Cancer Ther; 2021 Jul; 20(7):1257-1269. PubMed ID: 33947685
[TBL] [Abstract][Full Text] [Related]
11. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
[TBL] [Abstract][Full Text] [Related]
12. Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
Takashima Y; Kikuchi E; Kikuchi J; Suzuki M; Kikuchi H; Maeda M; Shoji T; Furuta M; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J; Konno S
Int J Cancer; 2020 Feb; 146(4):1114-1124. PubMed ID: 31199520
[TBL] [Abstract][Full Text] [Related]
13. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
[No Abstract] [Full Text] [Related]
14. Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines.
Sarcar B; Kahali S; Prabhu AH; Shumway SD; Xu Y; Demuth T; Chinnaiyan P
Mol Cancer Ther; 2011 Dec; 10(12):2405-14. PubMed ID: 21992793
[TBL] [Abstract][Full Text] [Related]
15. Anti-Tumor Effects of Wee1 Kinase Inhibitor with Radiotherapy in Human Cervical Cancer.
Lee YY; Cho YJ; Shin SW; Choi C; Ryu JY; Jeon HK; Choi JJ; Hwang JR; Choi CH; Kim TJ; Kim BG; Bae DS; Park W; Lee JW
Sci Rep; 2019 Oct; 9(1):15394. PubMed ID: 31659268
[TBL] [Abstract][Full Text] [Related]
16. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.
Chen X; Low KH; Alexander A; Jiang Y; Karakas C; Hess KR; Carey JPW; Bui TN; Vijayaraghavan S; Evans KW; Yi M; Ellis DC; Cheung KL; Ellis IO; Fu S; Meric-Bernstam F; Hunt KK; Keyomarsi K
Clin Cancer Res; 2018 Dec; 24(24):6594-6610. PubMed ID: 30181387
[TBL] [Abstract][Full Text] [Related]
17. AZD1775 and anti-PD-1 antibody synergistically sensitize hepatoma to radiotherapy.
Yin Y; Wang J; Yi J; Zhang K; Yin Z; Jin S; Zheng B
Chin Med J (Engl); 2024 Jan; 137(2):222-231. PubMed ID: 38167245
[TBL] [Abstract][Full Text] [Related]
18. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.
Jhuraney A; Woods NT; Wright G; Rix L; Kinose F; Kroeger JL; Remily-Wood E; Cress WD; Koomen JM; Brantley SG; Gray JE; Haura EB; Rix U; Monteiro AN
Mol Cancer Ther; 2016 Jul; 15(7):1669-81. PubMed ID: 27196765
[TBL] [Abstract][Full Text] [Related]
19. Wee1 kinase inhibitor AZD1775 potentiates CD8+ T cell-dependent antitumour activity via dendritic cell activation following a single high dose of irradiation.
Wang B; Sun L; Yuan Z; Tao Z
Med Oncol; 2020 Jul; 37(8):66. PubMed ID: 32696094
[TBL] [Abstract][Full Text] [Related]
20. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
Zhou L; Zhang Y; Chen S; Kmieciak M; Leng Y; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Dai Y; Grant S
Leukemia; 2015 Apr; 29(4):807-18. PubMed ID: 25283841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
